Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05076942 · ClinicalTrials.gov registry record · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
A Phase 2 study of Vulvar Cancer and Sentinel Lymph Node, sponsored by University Medical Center Groningen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT05076942 is a Phase 2 study of Vulvar Cancer and Sentinel Lymph Node that is actively recruiting participants, run by University Medical Center Groningen. The registered enrollment target is 157 participants, below the 444-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05076942, a Phase 2 study of Vulvar Cancer and Sentinel Lymph Node, is actively recruiting participants, sponsored by University Medical Center Groningen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Radiotherapy combined with cisplatin
Study Locations (20)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Michigan
- Spectrum Health at Butterworth Campus - Grand Rapids
- Munson Medical Center - Traverse City
North Carolina
- Duke University Medical Center - Durham
- Duke Women's Cancer Care Raleigh - Raleigh
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
- ProMedica Flower Hospital - Sylvania
California
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Florida
- Mount Sinai Medical Center - Miami Beach
Massachusetts
- Baystate Medical Center - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05076942
The ClinicalTrials.gov registry entry for NCT05076942 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (65% lower). The listed sponsor is University Medical Center Groningen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Vulvar Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT05076942 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, New Jersey, Michigan.
Frequently Asked Questions
What is clinical trial NCT05076942 about?
NCT05076942 is a clinical study titled "Groningen International Study on Sentinel Nodes in Vulvar Cancer-III". Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
What is the current status of trial NCT05076942?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2021-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT05076942 study?
This clinical trial studies the following conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases.
What interventions are being tested in trial NCT05076942?
The interventions under investigation include: Cisplatin (DRUG), Radiotherapy combined with cisplatin (RADIATION).
Who is sponsoring clinical trial NCT05076942?
This trial is sponsored by University Medical Center Groningen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05076942 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.